On September 24, 2025, the “2025 China Healthcare Decision-Makers Conference,” hosted by PHARMCUBE, along with the “China Innovative Drug Decade Achievement Tour,” was grandly held in Beijing. Biokin Pharmaceutical was awarded the “2025 China Innovative Drug Decade Glory Awards — Industry Leading Biotech Company” honor.

The past decade has been a “golden decade” for the Chinese innovative drug industry, marked by germination, growth, and blossoming. The sector has progressively transitioned from follow-on innovation to pioneering innovation, and from a domestic focus to boldly entering global markets. Original drugs developed by Chinese companies are increasingly reaching the world and gaining international recognition. 

Biokin Pharmaceutical has deeply cultivated the field of innovative drugs, adhering to the strategic positioning of “rooted in China, expanding globally, and becoming a multinational pharmaceutical company (MNC).” It is committed to establishing a globally leading advantage in the field of oncology medications. It strives to grow into an internationally competitive MNC, contributing more Chinese wisdom and solutions for global patients.